Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

<div>ddPCR anticipates clinical relapse in one patient with a TP53 mutation. (a) Assessment of target mutation by ddPCR during the monitoring on ctDNA in a patient (UPN1) relapsed at 12 months. TP53 p. Y205C c.614A&gt;G was present at 6 months (T4) after surgery, anticipating the patient’s clinical relapse by six months. (b) ddPCR scatterplot of target mutation (<i>y</i>-axis) vs. wild type (<i>x</i>-axis) on FFPE biopsy at diagnosis (upper plot) and on ctDNA at T4 (lower plot).</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy 

Figure 2 | Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy 